CLASS ACTION UPDATE for FSNN, APYX and CLDR: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

NEW YORK, NY / ACCESSWIRE / June 13, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links provided.

Fusion Connect, Inc. (OTC PINK: FSNN)

Class Period: August 14, 2018 - April 2, 2019
Lead Plaintiff Deadline : June 17, 2019
Join the action: https://www.zlk.com/pslra-1/fusion-connect-inc-loss-form?prid=1942&wire=1

The complaint alleges that Fusion made materially false and misleading statements, later admitting that the process used by certain of its Birch subsidiaries for capitalizing costs associated with the customer on-boarding process and the related judgments and estimates were not designed with sufficient precision, leading to an overstatement of the Company's earnings (or net loss) of between $1.7 million and $2.3 million in the quarter ending on June 30, 2018, and between $3.4 million and $4.1 million in the quarter ending September 30, 2018.

To learn more about the Fusion Connect, Inc. class action contact jlevi@levikorsinsky.com.

Apyx Medical Corporation (NASDAQ: APYX)

Class Period: August 1, 2018 - April 1, 2019
Lead Plaintiff Deadline : June 17, 2019
Join the action: https://www.zlk.com/pslra-1/apyx-medical-corporation-loss-form?prid=1942&wire=1

Allegations: Apyx Medical Corporation made materially false and/or misleading statements throughout the class period and/or failed to disclose that: (1) the clinical study on the use of J-Plasma for dermal resurfacing had not met its primary efficacy endpoint; (2) as a result, the clinical study did not support the Company's application for regulatory clearance; (3) as a result, the Company was unlikely to receive regulatory approval of J-Plasma for dermal resurfacing; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis.

To learn more about the Apyx Medical Corporation class action contact jlevi@levikorsinsky.com.

Cloudera, Inc. (NYSE: CLDR)

Class Period: April 28, 2017 - June 5, 2019
Lead Plaintiff Deadline : August 6, 2019
Join the action: https://www.zlk.com/pslra-1/cloudera-inc-loss-form?prid=1942&wire=1

Allegations: During the class period, Cloudera, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Cloudera was finding it increasingly difficult to identify large enterprises interested in adopting the Company's Hadoop-based platform; (ii) Cloudera needed to expend an increasing amount of capital on sales and marketing activities to generate new revenues, even as new revenue opportunities were diminishing; and (iii) Cloudera had materially diminished sales opportunities and prospects and could not generate annual positive cash flows.

To learn more about the Cloudera, Inc. class action contact jlevi@levikorsinsky.com.

You have until the lead plaintiff deadlines to request the court appoint as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP